Mainous Arch G, Rooks Benjamin J, Orlando Frank A
Department of Community Health and Family Medicine, University of Florida, Gainesville, FL, United States.
Department of Health Services Research Management, and Policy, University of Florida, Gainesville, FL, United States.
Front Med (Lausanne). 2022 May 12;9:891375. doi: 10.3389/fmed.2022.891375. eCollection 2022.
Inflammation in the initial COVID-19 episode may be associated with post-recovery mortality. The goal of this study was to determine the relationship between systemic inflammation in COVID-19 hospitalized adults and mortality after recovery from COVID-19.
An analysis of electronic health records (EHR) for patients from 1 January, 2020 through 31 December, 2021 was performed for a cohort of COVID-19 positive hospitalized adult patients. 1,207 patients were followed for 12 months post COVID-19 episode at one health system. 12-month risk of mortality associated with inflammation, C-reactive protein (CRP), was assessed in Cox regressions adjusted for age, sex, race and comorbidities. Analyses evaluated whether steroids prescribed upon discharge were associated with later mortality.
Elevated CRP was associated other indicators of severity of the COVID-19 hospitalization including, supplemental oxygen and intravenous dexamethasone. Elevated CRP was associated with an increased mortality risk after recovery from COVID-19. This effect was present for both unadjusted (HR = 1.60; 95% CI 1.18, 2.17) and adjusted analyses (HR = 1.61; 95% CI 1.19, 2.20) when CRP was split into high and low groups at the median. Oral steroid prescriptions at discharge were found to be associated with a lower risk of death post-discharge (adjusted HR = 0.49; 95% CI 0.33, 0.74).
Hyperinflammation present with severe COVID-19 is associated with an increased mortality risk after hospital discharge. Although suggestive, treatment with anti-inflammatory medications like steroids upon hospital discharge is associated with a decreased post-acute COVID-19 mortality risk.
新冠病毒病(COVID-19)初次发病时的炎症反应可能与康复后的死亡率相关。本研究的目的是确定COVID-19住院成人患者的全身炎症与COVID-19康复后死亡率之间的关系。
对2020年1月1日至2021年12月31日期间COVID-19呈阳性的住院成年患者队列的电子健康记录(EHR)进行分析。在一个医疗系统中,对1207例患者在COVID-19发病后进行了12个月的随访。在根据年龄、性别、种族和合并症进行调整的Cox回归分析中,评估了与炎症相关的C反应蛋白(CRP)的12个月死亡风险。分析评估了出院时开具的类固醇药物是否与后期死亡率相关。
CRP升高与COVID-19住院严重程度的其他指标相关,包括补充氧气和静脉注射地塞米松。CRP升高与COVID-19康复后的死亡风险增加相关。当CRP在中位数处分为高、低两组时,在未调整分析(HR = 1.60;95%CI 1.18,2.17)和调整分析(HR = 1.61;95%CI 1.19,2.20)中均存在这种效应。发现出院时口服类固醇药物处方与出院后较低的死亡风险相关(调整后HR = 0.49;95%CI 0.33,0.74)。
严重COVID-19患者出现的炎症反应增强与出院后死亡风险增加相关。尽管具有提示性,但出院时使用类固醇等抗炎药物进行治疗与COVID-19急性后期死亡风险降低相关。